Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF

Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with... There is no cure for pulmonary hypertension due to left heart disease (PH-LHD), but the rationale for using sildenafil to treat pulmonary arterial hypertension with heart failure with reduced ejection fraction (HFrEF) has been supported by short-term studies. We performed a meta-analysis to evaluate the effectiveness of sildenafil for PH-LHD with HFrEF. A systematic literature search of PubMed, EMBASE and the Cochrane Central Register of Controlled Trials was conducted from inception through October 2014 for randomized trials and for observational studies with control groups, evaluating the effectiveness of sildenafil to treat PH-LHD with HFrEF. Sildenafil therapy decreased pulmonary arterial systolic pressure both at the acute phase and at the 6-month follow-up (weighted mean difference (WMD): −6.03 mm Hg, P=0.02; WMD: −11.47 mm Hg, P<0.00001, respectively). Sildenafil was found to reduce mean pulmonary artery pressure (WMD: −3 mm Hg, P=0.0004) and pulmonary vascular resistance (WMD: −60.0 dynes cm−5, P=0.01) at the 3-month follow-up. Oxygen consumption at peak significantly increased to 3.66 ml min−1 kg−1 (P<0.00001), 3.36 ml min−1 kg−1 (P<0.00001) and 2.60 ml min−1 kg−1 (P=0.03) at 3, 6 and 12 months, respectively. There were significant reductions in ventilation to CO2 production slope of −2.00, −4.68 and −7.12 at 3, 6 and 12 months, respectively (P<0.00001). Sildenafil was superior to placebo regarding left ventricular ejection fraction at the 6-month follow-up (WMD: 4.35, P<0.00001), and it significantly improved quality of life. Sildenafil therapy could effectively improve pulmonary hemodynamics and cardiopulmonary exercise testing measurements of PH-LHD with HFrEF, regardless of acute or chronic treatment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hypertension Research Springer Journals

Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/comparative-effectiveness-of-sildenafil-for-pulmonary-hypertension-due-391Bfq7NNx

References (44)

Publisher
Springer Journals
Copyright
Copyright © 2015 by The Japanese Society of Hypertension
Subject
Medicine & Public Health; Medicine/Public Health, general; Internal Medicine; Public Health; Geriatrics/Gerontology; Obstetrics/Perinatology/Midwifery; Health Promotion and Disease Prevention
ISSN
0916-9636
eISSN
1348-4214
DOI
10.1038/hr.2015.73
Publisher site
See Article on Publisher Site

Abstract

There is no cure for pulmonary hypertension due to left heart disease (PH-LHD), but the rationale for using sildenafil to treat pulmonary arterial hypertension with heart failure with reduced ejection fraction (HFrEF) has been supported by short-term studies. We performed a meta-analysis to evaluate the effectiveness of sildenafil for PH-LHD with HFrEF. A systematic literature search of PubMed, EMBASE and the Cochrane Central Register of Controlled Trials was conducted from inception through October 2014 for randomized trials and for observational studies with control groups, evaluating the effectiveness of sildenafil to treat PH-LHD with HFrEF. Sildenafil therapy decreased pulmonary arterial systolic pressure both at the acute phase and at the 6-month follow-up (weighted mean difference (WMD): −6.03 mm Hg, P=0.02; WMD: −11.47 mm Hg, P<0.00001, respectively). Sildenafil was found to reduce mean pulmonary artery pressure (WMD: −3 mm Hg, P=0.0004) and pulmonary vascular resistance (WMD: −60.0 dynes cm−5, P=0.01) at the 3-month follow-up. Oxygen consumption at peak significantly increased to 3.66 ml min−1 kg−1 (P<0.00001), 3.36 ml min−1 kg−1 (P<0.00001) and 2.60 ml min−1 kg−1 (P=0.03) at 3, 6 and 12 months, respectively. There were significant reductions in ventilation to CO2 production slope of −2.00, −4.68 and −7.12 at 3, 6 and 12 months, respectively (P<0.00001). Sildenafil was superior to placebo regarding left ventricular ejection fraction at the 6-month follow-up (WMD: 4.35, P<0.00001), and it significantly improved quality of life. Sildenafil therapy could effectively improve pulmonary hemodynamics and cardiopulmonary exercise testing measurements of PH-LHD with HFrEF, regardless of acute or chronic treatment.

Journal

Hypertension Research – Springer Journals

Published: Jul 23, 2015

There are no references for this article.